Vital Signs - Long-Term Weight Loss Treatments

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on November 8, 2010, provides a strategic overview of key issues and trends relating to prescription medications for long-term weight loss. Additionally, a company spotlight is provided for Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on building a portfolio of novel, small molecule, best-in-class compounds that address large markets, including chronic kidney disease (CKD), diabetes and Alzheimer’s disease. Reimbursement and regulatory news from the FDA is also provided for the week of October 18, 2010.

Table of Contents

Vital Signs - Long-Term Weight Loss TreatmentsVital Signs: 8 Nov 2010This week's issue:




Related Research

Release Date : 08-Sep-17

Region : North America

Release Date : 22-Aug-17

Region : North America

Release Date : 08-Aug-17

Region : North America

Release Date : 31-Jul-17

Region : North America

Release Date : 27-Jul-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.